Oncotype DX Breast Recurrence Score

Publikationen

Klinische Validierung

Clinical Significance of the 21-Gene Signature (Oncotype DX) in Hormone Receptor-Positive Early Stage Primary Breast Cancer in the Japanese Population
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; Japan Breast Cancer Research Group-Translational Research Group
Cancer. 2010.

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer
K Albain, W Barlo, S Shak, G Hortobagyi, R Livingston, I-T Yeh, P Ravdin,R Bugarini, FL Baehner, NE Davidson, GW Sledge, E Winer, C Hudis, JIngle, E Perez, K Pritchard, L Shepherd, J Gralow, C Yoshizawa, D Allred, C Osborne, D Hayes
11(1): 55-65.

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Breast Cancer Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett, Jack Cuzick, Christopher James Wale, John Forbes, Elizabeth A. Mallon, Janine Salter, Emma Quinn, Anita Dunbier, Mitch Baum, Aman Buzdar, Anthony Howell, Roberto Bugarini, Frederick L. Baehner, and Steven Shak
28(11): 1829-1834.

Gene Expression and Benefit of Chemotherapy in Women with Node-Negative, Estrogen Receptor-Positive Breast Cancer
S Paik, G Tang, S Shak, C Kim, J Baker, W Kim, M Cronin, FL Baehner, D Watson, J Bryant, JP Costantino, C Geyer Jr., DL Wickerham, N Wolmark
24(23): 3726-3734.

A Population-Based Study of Tumor Gene Expression and Risk of Breast Cancer Death Among Lymph Node-Negative Patients
LA Habel, S Shak, M Jacobs, A Capra, C Alexander, M Pho, J Baker, MG Walker, D Watson, J Hackett, N Blick, D Greenberg, L Fehrenbacher, B Langholz, CP Quesenberry
R25.

A Multigene Assay to Predict Recurrence of Tamoxifen Treated Node-Negative Breast Cancer
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, D Watson, T Park, W Hiller, ER Fisher, DL Wickerham, J Bryant, N Wolmark
2817-2826.

Einfluss auf Therapieentscheidungen

Clinical Significance of the 21-Gene Signature (Oncotype DX) in Hormone Receptor-Positive Early Stage Primary Breast Cancer in the Japanese Population
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; Japan Breast Cancer Research Group-Translational Research Group
Cancer. 2010.

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer
K Albain, W Barlo, S Shak, G Hortobagyi, R Livingston, I-T Yeh, P Ravdin,R Bugarini, FL Baehner, NE Davidson, GW Sledge, E Winer, C Hudis, JIngle, E Perez, K Pritchard, L Shepherd, J Gralow, C Yoshizawa, D Allred, C Osborne, D Hayes
11(1): 55-65.

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Breast Cancer Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett, Jack Cuzick, Christopher James Wale, John Forbes, Elizabeth A. Mallon, Janine Salter, Emma Quinn, Anita Dunbier, Mitch Baum, Aman Buzdar, Anthony Howell, Roberto Bugarini, Frederick L. Baehner, and Steven Shak
28(11): 1829-1834.

Gene Expression and Benefit of Chemotherapy in Women with Node-Negative, Estrogen Receptor-Positive Breast Cancer
S Paik, G Tang, S Shak, C Kim, J Baker, W Kim, M Cronin, FL Baehner, D Watson, J Bryant, JP Costantino, C Geyer Jr., DL Wickerham, N Wolmark
24(23): 3726-3734.

A Population-Based Study of Tumor Gene Expression and Risk of Breast Cancer Death Among Lymph Node-Negative Patients
LA Habel, S Shak, M Jacobs, A Capra, C Alexander, M Pho, J Baker, MG Walker, D Watson, J Hackett, N Blick, D Greenberg, L Fehrenbacher, B Langholz, CP Quesenberry
R25.

A Multigene Assay to Predict Recurrence of Tamoxifen Treated Node-Negative Breast Cancer
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, D Watson, T Park, W Hiller, ER Fisher, DL Wickerham, J Bryant, N Wolmark
2817-2826.

Neoadjuvante Therapie

Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women with Locally Advanced Breast Cancer
L Gianni, M Zambetti, K Clark, J Baker, M Cronin, J Wu, G Mariani, J Rodriguez, M Carcangiu, D Watson, P Valagussa, R Rouzier, WF Symmans, JS Ross, GN Hortobagyi, L Pusztai, S Shak
23(29): 7265-7277.

Plattform Technologie

Measurement of Gene Expression in Archival Paraffin-Embedded Tissues
M Cronin, M Pho, D Dutta, JC Stephans, S Shak, MC Kiefer, JM Esteban, JB Baker
164(1): 35-42.

Biomarker discovery for colon cancer using a 761 gene RT-PCR assay
Kim M Clark-Langone*1, Jenny Y Wu1, Chithra Sangli1, Angela Chen1,James L Snable1, Anhthu Nguyen1, James R Hackett1,Joffre Baker1,Greg Yothers2, Chungyeul Kim2 and Maureen T Cronin1
8(279): 1471-2164-8-279.

Analytical Validation of the Oncotype DX Genomic Diagnostic Test Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor-Positive Breast Cancer
M Cronin, C Sangli, ML Liu, M Pho, D Dutta, A Nguyen, J Jeong, J Wu, KC Langone, D Watson
53(6): 1084-1091.

Testentwicklung

Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes
MA Cobleigh, B Tabesh, P Bitterman, J Baker, M Cronin, ML Liu, R Borchik, JM Mosquera, MG Walker, S Shak
11(24 Pt 1): 8623-8631.

Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy
FJ Esteva, AA Sahin, M Cristofanilli, K Coombes, SJ Lee, J Baker, M Cronin, MG Walker, D Watson, S Shak, GN Hortobagyi
11(9): 3315-3319.

Weitere Artikel zu Oncotype DX

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
Gong Tang, Steven Shak, Soonmyung Paik, Stewart J. Anderson, Joseph P. Costantino, Charles E. Geyer Jr., Eleftherios P. Mamounas, D. Lawrence Wickerham, Norman Wolmark
2010. Breast Cancer Research Treatment 2010.

Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers
R Simon
23(29): 7332-7341.

Problems and Solutions in the Evaluation of Hormone Receptors in Breast Cancer
DC Allred
25(15): 2433-2435.

Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory
Sunil S. Badve, Frederick L. Baehner, Robert P. Gray, Barrett H. Childs, Tara Maddala, Mei-Lan Liu, Steve C. Rowley, Steven Shak, Edith D. Perez, Lawrence J. Shulman, Silvana Martino, Nancy E. Davidson, George W. Sledge, Lori J. Goldstein, and Joseph A. Sparano
26(15): 2473-2481.

Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
JA Sparano, S Paik
26: 721-728.

Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen
S Paik
12(6): 631-635.

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
L Harris, H Fritsche, R Mennel, L Norton, P Ravdin, S Taube, MR Somerfield, DF Hayes, RC Bast Jr.
25(33): 5287-5312.

Adjuvant Chemotherapy for Patients with Estrogen Receptor-Positive Breast Cancer
HJ Burstein, S Paik, P Ravdin, K Albain

Haben Sie Fragen?

Kontaktieren Sie Uns

Kontakt

Kontakt
Making cancer care smarter.™
X

Erklärung zur Verwendung von Cookies X Diese Seite verwendet Cookies. Cookies speichern Informationen darüber, wie eine Website benutzt wird, beispielsweise welche Seiten am häufigsten besucht werden und ob die Benutzer Fehlermeldungen von Webseiten erhalten. Diese Cookies erfassen keine Informationen, die einem Benutzer direkt zugeordnet werden können. Alle von diesen Cookies gesammelten Informationen dienen ausschließlich der Website-Optimierung. Mit dem Besuch dieser Website erklären Sie sich damit einverstanden, dass wir solche Cookies auf Ihrem Computer oder sonstigen Geräten zur Internetnutzung absetzen.